Infliximab Use Not Tied to Malignancy in Pediatric IBD Infliximab Use Not Tied to Malignancy in Pediatric IBD

Immunosuppressive therapy with infliximab (Remicade, Janssen) for inflammatory bowel disease (IBD) in pediatric patients is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis (HLH), according to a Janssen study.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Gastroenterology News Source Type: news